CY1108676T1 - Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων - Google Patents

Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων

Info

Publication number
CY1108676T1
CY1108676T1 CY20081101427T CY081101427T CY1108676T1 CY 1108676 T1 CY1108676 T1 CY 1108676T1 CY 20081101427 T CY20081101427 T CY 20081101427T CY 081101427 T CY081101427 T CY 081101427T CY 1108676 T1 CY1108676 T1 CY 1108676T1
Authority
CY
Cyprus
Prior art keywords
ophthalmic
poloxamine
tonikotitas
glykolis
medicament
Prior art date
Application number
CY20081101427T
Other languages
English (en)
Inventor
Geoffrey Robert Owen
Amy C Brooks
Gustav Graff
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Publication of CY1108676T1 publication Critical patent/CY1108676T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Abstract

Αποκαλύπτονται τοπικές συνθέσεις υδατικού εναιωρήματος δυσδιάλυτων οφθαλμικών φαρμάκων. Οι συνθέσεις περιλαμβάνουν ένα συνδυασμό ενός μη ιοντικού τασιενεργού τύπου πολοξαμίνης και ενός παράγοντα ρυθμίσεως τονικότητας τύπου γλυκόλης όπως η προπυλενιογλυκόλη.
CY20081101427T 2005-05-10 2008-12-10 Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων CY1108676T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67951005P 2005-05-10 2005-05-10
EP06759259A EP1906916B1 (en) 2005-05-10 2006-05-08 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders

Publications (1)

Publication Number Publication Date
CY1108676T1 true CY1108676T1 (el) 2014-04-09

Family

ID=37087751

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101427T CY1108676T1 (el) 2005-05-10 2008-12-10 Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων

Country Status (19)

Country Link
US (1) US20060257486A1 (el)
EP (1) EP1906916B1 (el)
JP (1) JP4968955B2 (el)
KR (1) KR20080011311A (el)
CN (1) CN101175476B (el)
AT (1) ATE412402T1 (el)
AU (1) AU2006244245B2 (el)
BR (1) BRPI0608774A2 (el)
CA (1) CA2607014A1 (el)
CY (1) CY1108676T1 (el)
DE (1) DE602006003438D1 (el)
DK (1) DK1906916T3 (el)
ES (1) ES2313670T3 (el)
MX (1) MX2007014084A (el)
PL (1) PL1906916T3 (el)
PT (1) PT1906916E (el)
SI (1) SI1906916T1 (el)
WO (1) WO2006121964A2 (el)
ZA (1) ZA200709296B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1885336B1 (en) * 2005-05-10 2009-04-15 Alcon, Inc. Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
MX2011008680A (es) * 2009-03-03 2011-09-08 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
DK2965749T3 (en) * 2009-12-03 2018-08-27 Novartis Ag Nanoparticle suspensions containing carboxyvinyl polymer
AU2010328186B2 (en) 2009-12-08 2014-12-18 Case Western Reserve University Compounds and methods of treating ocular disorders
KR20130100273A (ko) * 2010-08-27 2013-09-10 와카모토 세이야꾸 가부시끼가이샤 점안용 수성 조성물
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
CN104706579A (zh) * 2015-03-12 2015-06-17 广州仁恒医药科技有限公司 一种夫西地酸滴眼液及其制备方法
CN111285845B (zh) * 2020-02-11 2021-01-01 深圳厚存纳米药业有限公司 末端官能团化的泊洛沙胺衍生物
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
CA3206106A1 (en) * 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
US20240108609A1 (en) * 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
JPH0662417B2 (ja) * 1987-12-25 1994-08-17 参天製薬株式会社 抗アレルギー点眼液
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5631005A (en) * 1994-09-21 1997-05-20 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
US5631004A (en) * 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
EP0970175B1 (en) * 1997-07-29 2002-10-02 Alcon Laboratories, Inc. Conditioning solutions for hard contact lens care
US6037328A (en) * 1998-12-22 2000-03-14 Bausch & Lomb Incorporated Method and composition for rewetting and preventing deposits on contact lens
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1249249A1 (en) * 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmic composition
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US20020115578A1 (en) * 2000-12-14 2002-08-22 Groemminger Suzanne F. Composition for cleaning and wetting contact lenses
US6646003B2 (en) * 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac
JP2003137775A (ja) * 2001-10-31 2003-05-14 Menicon Co Ltd 眼科用組成物
US20030133905A1 (en) * 2001-12-20 2003-07-17 Zhenze Hu Composition for treating contact lenses in the eye
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
AU2003217810C9 (en) * 2002-02-28 2008-06-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US20040115270A1 (en) * 2002-12-13 2004-06-17 Dharmendra Jani Absorption and controlled release of polyethers from hydrogel biomaterials
WO2004084877A1 (ja) * 2003-03-26 2004-10-07 Menicon Co., Ltd. 眼科用組成物
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
EP1885336B1 (en) * 2005-05-10 2009-04-15 Alcon, Inc. Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders

Also Published As

Publication number Publication date
JP4968955B2 (ja) 2012-07-04
EP1906916B1 (en) 2008-10-29
AU2006244245B2 (en) 2010-11-18
AU2006244245A1 (en) 2006-11-16
BRPI0608774A2 (pt) 2010-01-26
SI1906916T1 (sl) 2009-02-28
EP1906916A2 (en) 2008-04-09
KR20080011311A (ko) 2008-02-01
MX2007014084A (es) 2008-02-07
ZA200709296B (en) 2009-01-28
CN101175476B (zh) 2011-11-16
ATE412402T1 (de) 2008-11-15
CN101175476A (zh) 2008-05-07
ES2313670T3 (es) 2009-03-01
US20060257486A1 (en) 2006-11-16
CA2607014A1 (en) 2006-11-16
DK1906916T3 (da) 2009-01-19
PL1906916T3 (pl) 2009-02-27
WO2006121964A2 (en) 2006-11-16
DE602006003438D1 (de) 2008-12-11
WO2006121964A3 (en) 2007-03-22
PT1906916E (pt) 2008-12-10
JP2008540533A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
WO2020016659A3 (en) Multiparticulate formulations of cannabinoids
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
PA8680701A1 (es) Derivados de oxindol
BRPI0509863A (pt) liberação de fármaco para fundo de olho
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
BRPI0510778B8 (pt) composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
SE0101932D0 (sv) Pharmaceutical combinations
BRPI0812494A2 (pt) Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo
UY27275A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
HRP20070081T3 (en) Nasal pharmaceutical composition of piribedil
ECSP088236A (es) Formas y composiciones de dosificaciones farmacéuticas
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
DE60233647D1 (de) Reduziertes vitamin b2 enthaltende arzneimittel
CY1115063T1 (el) Μεθοδος και συνθεση για τη θεραπεια φλεγμονωδων διαταραχων